Advances in Chronic Kidney Disease
Volume 14, Issue 3 , Pages e17-e26 , July 2007

Drug Dosing Considerations in Alternative Hemodialysis

  • Brian S. Decker

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    • ,
  • Bruce A. Mueller

      Affiliations

    • Department of Clinical Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI, USA
    • ,
  • Kevin M. Sowinski

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    • Department of Pharmacy Practice, Purdue University School of Pharmacy and Pharmaceutical Sciences, West Lafayette and Indianapolis, IN, USA.
    • Corresponding Author InformationAddress correspondence to: Kevin M. Sowinski, Pharm.D., FCCP, Department of Pharmacy Practice, Purdue University School of Pharmacy and Pharmaceutical Sciences, W7555 Myers, WHS, 1001 West 10th St., Indianapolis, IN 46202-2879.

References 

  1. U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States,National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006
  2. Henrich WL. Principles and Practice of Dialysis. Philadelphia, PA: Lippincott Williams & Wilkins; 2004;
  3. Matzke GR, Comstock TJ. Influence of renal function and dialysis on drug disposition. In:  Burton ME,  Shaw LM,  Schentag JJ,  Evans WE editor. Applied Pharmacokinetics and Pharmacodynamics, Principles of Therapeutic Drug Monitoring. Philadelphia, PA: Lippincott Williams & Wilkins; 2006;p. 187–212
  4. Atkinson AJ, Susla GM. Pharmacokinetics in patients receiving renal replacement therapy. In:  Atkinson AJ,  Abernethy DR,  Daniels CE,  Dedrick RL,  Markey SP editor. Principles of Clinical Pharmacology. New York, NY: Elsevier; 2007;p. 59–72
  5. Aronoff GR, Berns JS, Brier ME. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. (ed 4). Philadelphia, PA: American College of Physicians; 1999;
  6. Suri R, Depner TA, Blake PG, et al. Adequacy of quotidian hemodialysis. Am J Kidney Dis. 2003;42:42–48
  7. Locatelli F, Buoncristiani U, Canaud B, et al. Dialysis dose and frequency. Nephrol Dial Transplant. 2005;20:285–296
  8. Lindsay RM, Heidenheim AP, Leitch R, et al. Short daily versus long nocturnal hemodialysis. ASAIO J. 2001;47:449–455
  9. Pierratos A. Daily hemodialysis: An update. Curr Opin Nephrol Hypertens. 2002;11:165–171
  10. Lacson E, Diaz-Buxo JA. Daily and nocturnal hemodialysis: How do they stack up?. Am J Kidney Dis. 2001;38:225–239
  11. Saner E, Nitsch D, Descoeudres C, et al. Outcome of home hemodialysis patients: A case-cohort study. Nephrol Dial Transplant. 2005;20:604–610
  12. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998;53:1399–1404
  13. Messa PM, Gropuzzo M, Boscutti CG, et al. Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial Transplant. 1998;13(suppl 6):43–48
  14. Clark WR, Hamburger RJ, Lysaught MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int. 1999;56:2005–2015
  15. Manley HJ, Bailie GR, McClaran ML, et al. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int. 2003;63:1072–1078
  16. Matsuo H, Hayashi J, Ono K, et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: A new dosing modality. Antimicrob Agents Chemother. 1997;41:2597–2601
  17. Dang L, Duffull S. Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol. 2006;46:662–673
  18. Teigen MM, Duffull S, Dang L, et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006;46:1259–1267
  19. Leypoldt JK, Cheung AK, Deeter RB, et al. Kinetics of urea and beta-microglobulin during and after short hemodialysis treatments. Kidney Int. 2004;66:1669–1676
  20. Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis. 2002;40:1211–1218
  21. Clark WR, Leypoldt JK, Henderson LW, et al. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 1999;10:601–609
  22. Twardowski ZJ. Treatment time and ultrafiltration rate are more important in dialysis prescription than small molecule clearance. Blood Purif. 2007;25:90–98
  23. Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs. 2003;27:808–814
  24. Sowinski KM, Magner S, Lucksiri A, et al. Solute removal characteristics of the CAHP-210 hemodialyzer: In vitro and in vivo performance. Pharmacotherapy. 2001;21:1288–1289
  25. Sowinski KM, Lucksiri A, Kays MB, et al. Levofloxacin pharmacokinetics in end-stage renal disease and removal by the CAHP-210 hemodialyzer. Am J Kidney Dis. 2003;42:342–349
  26. Lucksiri A, Scott MK, Mueller BA, et al. CAHP-210 dialyzer influence on intradialytic vancomycin bioavailability. Nephrol Dial Trans. 2002;17:1649–1654
  27. Sowinski KM, Mueller BA, Grabe DW, et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis. 2001;37:766–776
  28. Spivey JM, Blum RA, Nix DE. Mathematic modeling of drug disposition and postdialysis rebound in patients requiring hemodialysis. Pharmacotherapy. 1992;12:201–206
  29. D’Argenio DZ, Schumitzky A. ADAPT II Release 4, User’s Guide. Los Angeles, CA: Biomedical Simulations Resource, University of Southern California; 1997;
  30. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10
  31. Pai AB, Pai MP. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis. Adv Chronic Kidney Dis. 2006;13:259–270

PII: S1548-5595(07)00048-1

doi: 10.1053/j.ackd.2007.03.004

Advances in Chronic Kidney Disease
Volume 14, Issue 3 , Pages e17-e26 , July 2007

Article Tools

* Image Usage & Resolution